

Paediatric IBD cases with confirmed or highly suspected SARS-CoV-2 infection

Ten cases have been reported until March 31st, 2020 from the 102 sites affiliated with the Pediatric IBD Porto group of ESPGHAN (Table). Nine were treated with immunosuppressants and nine had a mild infection and none of the ten needed admission. The underlying IBD remained stable during the infection and the IBD-related medications were not held in any of the cases.

	Age (yrs), Gender, IBD type	Disease duration (yrs)	Paris classification	PGA of disease activity	Longitudinal PGA of the year prior to infection	PUCAI/ wPCDAI prior to infection	Medications at infection	Past medications	COVID-19 diagnosis	Presenting COVID-19 symptoms	Severity of infection
1	14, F, CD	4.3	A1aL3B2G0	Mild disease activity	Moderate	20	5ASA, thiopurines, adalimumab	Methotrexate, infliximab	Confirmed	Fever, cough	Mild
2	18, M, CD	4.8	A1bL2B1G0	Deep remission	None	0	Infliximab		Confirmed	Fatigue, cough	Mild
3	14.8, M, UC	1.2	E3S0	Deep remission	None	0	5ASA, thiopurines	Steroids, 5ASA, thiopurines	Confirmed	Slight rhinitis	Mild
4	16, M, CD	4.6	A1bL3B2G1	Clinical remission	None	10	Adalimumab		Suspected	Fatigue, myalgia	Mild
5	14, M, IBD-U	5.9	E2S0	Deep remission	None		5ASA, thiopurines		Suspected	Fatigue, myalgia	Mild
6	18, F, UC	3.4	E4S0	Deep remission	Mild	0	5ASA, thiopurines, vedolizumab		Confirmed	Anosmia, ageusia, mild cough.	Mild
7	18, F, CD	0.2	A2L1B1G0	Moderate disease activity	Moderate	70	Steroids		Confirmed	Low grade fever, mild chest pain	Mild
8	17, M, CD	5	Unknown	Unknown	Unknown	Unknown	Infliximab	Unknown	Confirmed	Asymptomatic	Mild
9	15.2, F, CD	0.4	A1bL3B2G0	Clinical remission	Moderate	0	Adalimumab		Suspected	Cough and rhinitis	Mild
10	14.6, M, UC	4.6	E4S1	Mild disease activity	Moderate	10	5ASA, thiopurines, vedolizumab	Steroids, Infliximab, Golimumab	Suspected	Mouth ulcers watery diarrhea mo blood abdominal pain fatigue fever 39-40°C	Moderate

CD, Crohn's disease; UC, ulcerative colitis; PGA, physician global assessment; PUCAI, pediatric UC activity index; wPCDAI, weighted paediatric CD activity index;

Comments to the table

1. The four suspected cases: household first-degree relative had concurrent confirmed infection but the child was not tested as per local testing policy since they has only mild presentation
2. None required admission
3. None of the IBD-related medications were stopped due to the SARS-CoV-2 infection
4. No worsening of the IBD has been reported in any of the children, except case #11 who had diarrhoea (possibly SARS-CoV-2 related)
5. Patients #1-8 and #10-11 did not suffered from other chronic disease; patient #9 had cardiovascular disease
6. Cases reported from the Porto group sites in: France, United Kingdom, Italy, Spain, Israel; Case #9 was reported from the SECURE-IBD registry